Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): A retrospective cohort analysis

J. M. Foran, A. J. Norton, I. N.M. Micallef, D. C. Taussig, J. A.L. Amess, A. Z.S. Rohatiner, T. A. Lister

Research output: Contribution to journalArticlepeer-review

81 Scopus citations

Abstract

A retrospective analysis of CD20 expression following rituximab for B-cell non-Hodgkin's lymphoma demonstrated a significant change in immunophenotype in 6/25 (24%) patients with persistent bone marrow (BM) infiltration. In three out of six patients, the B cells were uniformly CD20/CD79α+, consistent with frank loss of CD20 expression. In the remaining three cases, the BM infiltrate was predominantly (>80%) CD20/CD79α+. Two of the former but none of the latter three cases achieved a clinical response. In three further cases, the post-treatment BM infiltrate was composed entirely of benign or reactive CD3+ T cells. Frank loss of CD20 was not seen in 25 post-treatment lymph node biopsies. Immunophenotyping is therefore an important adjunct in the diagnosis of BM infiltration following rituximab.

Original languageEnglish (US)
Pages (from-to)881-883
Number of pages3
JournalBritish journal of haematology
Volume114
Issue number4
DOIs
StatePublished - 2001

Keywords

  • B cell
  • CD20
  • Immunohistochemistry
  • Non-Hodgkin's lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): A retrospective cohort analysis'. Together they form a unique fingerprint.

Cite this